The Institute for Quality and Efficiency in Health Care (IQWiG) investigated in a dossier assessment whether propranolol offers an added benefit in comparison with the appropriate comparator therapy in infants with proliferating infantile haemangioma (sometimes called "strawberry mark").
According to the findings, there is an indication of major added benefit of propranolol (structure) in some children, i.e. those with haemangioma with a risk of permanent scars or disfigurement. In contrast, an added benefit is not proven for children with life- or function-threatening haemangioma, or with ulcerated haemangioma with pain or lack of response to simple wound care measures, because informative data are lacking.
Study indicates major added benefit of propranolol in some children with haemangioma
No comments:
Post a Comment